Completed PHASE3 INTERVENTIONAL NCT00333450

Immune Memory Evaluation in Children Following a Primary Vaccination With Pneumococcal Conjugate Vaccines.

Multicentre Immune Memory Study in Healthy Children Following a 3 Dose Primary Vaccination With Prevenar or GSK Biologicals' Pneumococcal Conjugate Vaccine Via the Administration of a Single Booster Dose of Pneumovax 23

Sponsor: GlaxoSmithKline

Conditions Infections, Streptococcal

Interventions Pneumococcal vaccine

Updated 6 times since 2017 Last updated: Oct 6, 2016 Started: Aug 31, 2006 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Infections, Streptococcal and is currently completed. GlaxoSmithKline leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bad Lobenstein, Germany , Bad Oeynhausen, Germany , Berlin, Germany , Erkrath, Germany , Frankenthal, Germany , Goch, Germany , Heiligenhaus, Germany , Leipzig, Germany , Mainz, Germany , Mannheim, Germany and 15 more locations